Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | LPL | P06858 | 7/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24959140 | 0.88 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL3410296 | 0.88 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL1869990 | 0.87 | FFAR1 (0.60) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL29966774 | 0.86 | FFAR1 (0.53) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL3405330 | 0.86 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL98872 | 0.86 | FFAR1 (0.53) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL253540 | 0.84 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL24609489 | 0.84 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL19002004 | 0.84 | FFAR1 (0.51) | FFAR1LPLLIPGDGAT1CA1 | |
| SCHEMBL19629502 | 0.84 | FFAR1 (0.51) | FFAR1LPLLIPGDGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | HGF, MET, HGFAC | FFAR1 3081/4885LPL 2195/4885LIPG 853/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | FFAR1 4031/4885LPL 1677/4885LIPG 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.